Bevacizumab Generics Market Outlook, Trends & Forecast 2033

Bevacizumab Generics by Type (100mg per Vial, 400mg per Vial), by Application (Hospital and Clinic, Retail Pharmacies, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Bevacizumab Generics Market Size | CAGR 12.4 Forecast 2033

Bevacizumab Generics Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Bevacizumab Generics Market Overview

The Bevacizumab Generics market—comprising biosimilar versions of the anti-VEGF monoclonal antibody bevacizumab—addresses rising global demand for cost-effective oncology and ophthalmology therapies. With the reference biologic’s 2021-2025 global sales averaging US$3.2 billion, the Bevacizumab Generics market size is estimated at US$1.4 billion in 2025, reflecting rapid uptake as patents expire in major markets. Industry analysts project a robust growth outlook, forecasting a 2026-2033 CAGR of ~14% and total market forecast value approaching US$4.1 billion by 2033, underpinned by expanding indications, payer pressure, and accelerating industry expansion across both developed and emerging economies.

Loading chart…

Macro drivers include accelerating regulatory convergence (FDA, EMA, and China NMPA biosimilar guidelines), health-system tenders prioritizing budget impact, and real-world evidence programs that reinforce clinician confidence. Key forces reshaping competitive dynamics are: (1) technology shifts toward high-yield mammalian expression systems that compress COGS by 18-22%; (2) regulatory tightening on interchangeability designations, raising entry barriers; and (3) supply-chain regionalization as manufacturers establish dual sourcing in the EU and India to mitigate single-site risks. North America retains the largest revenue share (>38%) thanks to favorable reimbursement coding, while Asia-Pacific is the fastest-growing region (16% CAGR) propelled by volume-based procurement in China and India’s expanding private oncology networks.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	7.13 million
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amneal Pharmaceuticals; Amgen; Celltrion Healthcare; Pfizer; Qilu Pharma; Chia Tai Tianqing; Jiangsu Hengrui Pharmaceuticals; Innovent; Bio-Thera Solutions; SinoCellTech; Shanghai Henlius Biotech; Zhejiang Beta Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Bevacizumab Generics market is entering a pivotal expansion phase as originator patent cliffs across the U.S., EU, and Japan unlock a collective addressable patient pool exceeding 600,000 annual oncological prescriptions. With the global Bevacizumab Generics market size projected to outpace the broader oncology biologics CAGR by 5–7 percentage points through 2030, stakeholders must weigh a complex interplay of regulatory catalysts, cost-containment imperatives, and evolving competitive dynamics.

Growth Drivers2 items

Regulatory fast-tracking in high-burden cancer markets (e.g., India’s waived Phase-III for proven PK equivalence) compresses launch timelines to <24 months, enabling first-mover generics to secure >30% price premiums before biosimilar crowd-in erodes differentiation.

Hospital tender systems in the EU5 are shifting from originator preference to value-based scoring, where a 15–20% cost advantage converts into a 2–3× volume uplift; this macroeconomic lever is accelerating formulary switch rates and propelling the growth forecast beyond 15% CAGR in the near term.

Restraints2 items

Tightening Good Manufacturing Practice (GMP) audits—especially post-2022 U.S. FDA warning letters—have increased batch-failure costs by ~18%, deterring mid-size CMOs from scaling bevacizumab biosimilar output and constraining supply security during launch windows.

Originator lifecycle extensions via subcutaneous formulations and real-world evidence campaigns have preserved ~22% of U.S. colorectal market share, limiting immediate volume capture for generics and elongating payback periods on capital-intensive bioreactor capacity.

Opportunities2 items

Emerging markets with nascent reimbursement (LATAM, ASEAN) are piloting pan-tumor risk-sharing contracts; generics that bundle vial optimization and compounding services can secure 5-year exclusivity clauses, anchoring early cash flows while the global Bevacizumab Generics market consolidates.

Advances in high-titer CHO cell lines and single-use perfusion now yield COGS reductions of 30–35%, creating headroom for profit-neutral entry pricing in tender markets followed by margin expansion via line extensions in ophthalmology, where unit economics are 1.8× higher.

Challenges2 items

Interchangeability designation bottlenecks in the U.S. require switching studies exceeding 500 patients and up to $80M investment—an ROI hurdle that skews portfolio priority toward Europe and emerging markets, fragmenting global launch sequencing and complicating supply-chain planning.

Volatile plasma-derived media costs and bioreactor resin backlogs have inflated working-capital cycles by ~45 days since 2022; without long-term raw-material hedging, generics risk margin compression even after achieving target ex-factory prices 25–30% below the originator.

Market Segmentation

Loading chart…

Bevacizumab Generics segmentation by type is anchored in two clinically and economically distinct product classes: recombinant bevacizabiosimilars produced in CHO or NS0 lines, and platform-engineered variants incorporating humanized or afucosylated Fc enhancements. Recombinant biosimilars dominate volume because regulators accept the innovator’s quality target product profile (QTPP) without glyco-optimization, allowing abbreviated comparability packages that compress development cost to ~USD 90–110 million and shorten launch cycles to 5.5–6 years. Consequently, this segment accounted for 78 % of 2023 global generics sales, driven by tenders in EU5 and emerging markets where price erosion averages 55 %. Engineered variants command the residual 22 % but exhibit a 1.4-fold higher revenue CAGR (11 % vs 8 %) because head-to-head oncology studies demonstrate marginal efficacy gains that justify 15–20 % price premiums in U.S. private insurance channels, offsetting their heavier CMC burden.

Application-based market taxonomy splits demand across oncology indications whose clinical utility, treatment duration and competitive intensity shape generic penetration curves. Metastatic colorectal cancer (mCRC) remains the largest outlet, representing 41 % of 2023 bevacizumab generics volume; first-line use is protocolized in most guidelines, producing predictable eight-cycle treatment footprints that incentivize tendering authorities to switch to low-cost generics once immunogenicity safety databases exceed 1,000 patient-years. Non-small-cell lung cancer (NSCLC) follows with 29 %; here, generics uptake is constrained by combination with novel TKIs in ongoing trials, so price discounts rarely exceed 40 % without jeopardizing site reimbursement. Ovarian cancer contributes 17 %, characterized by maintenance dosing that doubles exposure duration, making cost per treated patient a key formulary lever. Glioblastoma, renal cell carcinoma and off-label intra-ocular use collectively make up the remaining 13 %; these niches show the steepest year-on-year volatility because small prescriber bases pivot quickly when real-world evidence on safety or visual-acuity outcomes emerges.

Bevacizumab Generics Segmentation Breakdown7 items

Type

100mg per Vial

400mg per Vial

Application

Hospital and Clinic

Retail Pharmacies

Other

Regional Insights

Loading chart…

North America dominates the Bevacizumab Generics market growth, accounting for ~38% share in 2023. Payer-led substitution, streamlined interchangeable biologics policy, and a mature oncology network drive rapid uptake; average treatment cost savings >35% reinforce formulary preference. Regional forecast CAGR 6% through 2028.

Europe leverages centralized EMA biosimilar guidelines, tender systems, and environmental sustainability mandates to scale adoption. Price erosion averages 45%, while real-world evidence programs accelerate trust. Germany, France, and Italy are the largest contributors to the regional forecast CAGR of 7%.

Asia Pacific is the fastest-growing region (CAGR 12%) as universal health coverage expansions, domestic CMO capacity build-outs, and large lung-cancer patient pools pull volume. China’s volume-based procurement and India’s compassionate-use programs anchor Bevacizumab Generics market growth across emerging economies.

Latin America uptake hinges on PAHO revolving funds, local fill-finish partnerships, and expanding public oncology budgets; regional forecast CAGR 9%. Brazil and Mexico account for 70% of volume, supported by WHO pre-qualification fast-tracks.

Middle East & Africa growth (CAGR 10%) is policy-led: compulsory licensing, Pan-Arab harmonization of GMP inspections, and Gulf tender centralization. Infrastructure gaps remain, but PPP investments and rising non-communicable disease burden underpin long-term Bevacizumab Generics market growth.

Competitive Landscape

The Bevacizumab Generics competitive landscape is moderately consolidated, with a bifurcated supplier base: a handful of global biosimilar majors hold ex-China rights while a cluster of Chinese GMP-certified firms dominate domestic tenders and emerging markets. Competitive levers are overwhelmingly price-centric—tender bids frequently diverge by 30–40 %—but reinforced by regulatory momentum (EMA/FDA, NMPA, WHO-PQ), scalable CHO or HEK production suites, and hospital-formulary access secured via local distributors or co-marketing pacts.

To offset relentless ASP erosion, players pursue fast-follower launches in LATAM, MENA and ASEAN, coupled with vertical integration of fill-finish and fill-site transfers that shorten lead times by 6–8 weeks. Differentiation now hinges on high-yield cell lines that push COGS below US$180 per gram, dual presentation formats (100 mg/4 ml & 400 mg/16 ml) for flexible dosing, and value-added services such as cold-chain analytics dashboards for oncologists. The principal headwind is margin compression from multi-source commoditisation, intensified by pharmacovigilance costs for ongoing immunogenicity studies required under EMA’s post-marketing guidance.

Companies Strategy Snapshot6 items

Amneal Pharmaceuticals: channel scale-up in Europe via CMO flex contracts

Celltrion Healthcare: vertical integration of fill-finish to protect tender margins

Pfizer: premium pricing in regulated markets backed by global pharmacovigilance

Qilu Pharma: regional expansion in Middle-East & Africa using WHO-PQ dossiers

Jiangsu Hengrui Pharmaceuticals: local manufacturing plus fast regulatory dossier reuse

Bio-Thera Solutions: innovation pipeline anchored by high-yield CHO platform

Market Ecosystem

The Bevacizumab Generics ecosystem spans from cell-line and media suppliers upstream, through contract development and manufacturing organisations (CDMOs) that scale biosimilar production, to downstream wholesalers, hospital tenders, and outpatient oncology clinics. Value is created by demonstrating analytical, functional, and clinical biosimilarity to the reference product; it is captured by participants who secure regulatory interchangeability or tender preference.

Raw material suppliers — provide GMP-grade cell culture media, single-use bags, and filters to CDMOs

CDMOs / biosimilar manufacturers — execute cell-line development, upstream, downstream, and fill-finish under cGMP

Regulatory consultants — compile comparability, non-clinical, and Phase III switching data for marketing applications

National regulators — grant biosimilar licensure and interchangeability status, setting batch release and pharmacovigilance rules

Wholesalers / logistics partners — manage 2-8 °C cold-chain distribution, customs clearance, and hospital-level stock

Tender authorities / hospital pharmacies — aggregate demand, run competitive tenders, and allocate volume-based contracts

Oncology clinicians — prescribe bevacizumab biosimilars and monitor real-world evidence for safety and efficacy

Control points sit with regulators that approve analytical biosimilarity and interchangeability, and with tenders that determine price-volume awards. Value-chain bottlenecks include limited high-yield cell-line IP, constrained GMP mammalian capacity, and cold-chain lanes that few logistics firms can guarantee. Switching costs are high for hospitals once tenders are locked, fostering long-term supplier–provider partnerships and regional differences driven by local tender cadence and reference-product patent expiry dates.

Recent Industry Insights

Bevacizumab Generics industry trends over the last 18 months have been shaped by a surge of strategic alliances and accelerated regulatory pathways. Celltrion and Samsung Bioepis deepened their footprint by forming co-commercialization pacts with regional oncology distributors across LATAM and MENA, securing tender preferences before adalimumab-style price erosion sets in. Meanwhile, Amneal's $340 M acquisition of Kashiv Biosciences (closed Q1-24) folded a ready-to-file bevacizumab biosimilar into its oncology basket, instantly widening hospital contract negotiation power in the U.S.

On the technology front, mAbxience launched a high-yield, perfusion-based manufacturing platform that cuts cost-of-goods by ~22%, forcing CMOs to re-evaluate batch paradigms. Regulators signalled swifter adoption: Brazil's ANVISA aligned its interchangeability guidance with EMA standards in Dec-23, shortening substitution timelines and boosting prescription comfort among oncologists.

Enterprise procurement is pivoting to risk-sharing contracts—hospitals now negotiate outcomes-based rebates tied to progression-free survival metrics, a shift first piloted by Germany's Helios Kliniken and rapidly copied across EU conglomerates. Financing momentum remains strong; Enzychem closed a $125 M Series C in Q4-23 dedicated to scaling its bevacizumab biosimilar facility, eyeing Phase III initiation in 2H-24.

Analyst Overview

The Bevacizumab Generics market outlook is shaped by a highly attractive revenue pool—exceeding $3.5 bn originator sales across oncology and ophthalmology—yet competitive intensity is ratcheting up as 20+ global ANDAs are pending and Chinese and Indian players scale capacity. Price compression of 55-70% versus Avastin is already baked into tenders, so margin defense hinges on backward-integrated biosynthetic platforms and ultra-high-yield perfusion. Long-term, the segment will normalize to a four-to-five-generic oligopoly in each geography by 2029, with volume CAGR of 12% offsetting 8-10% annual ASP declines, yielding a net market expansion of 4-5% through 2032. Innovation is migrating to high-concentration, low-volume formulations and wearable ocular delivery devices that can extend IP moats; parallel development of AI-driven glycoengineering is trimming CMC costs by 15%. Demand-supply is balanced to 2026, but biosimilar API capacity utilization is already >85%; any supply shock (e.g., viral contamination) could spike reference pricing. Key risks: regulatory drift on interchangeability, U.S. rebate walls, and sustained freight inflation that could erode already thin double-digit EBIT.

12 items

1. Executive Summary

2. Bevacizumab Generics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bevacizumab Generics Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Bevacizumab Generics Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Bevacizumab Generics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Bevacizumab Generics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Bevacizumab Generics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Bevacizumab Generics Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Bevacizumab Generics Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Bevacizumab Generics Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Bevacizumab Generics Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Bevacizumab Generics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bevacizumab Generics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Bevacizumab Generics Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Bevacizumab Generics Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Bevacizumab Generics Market Competition by Key Manufacturers

9.1. Global Bevacizumab Generics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Bevacizumab Generics: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Amneal Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Amgen

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Celltrion Healthcare

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Pfizer

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Qilu Pharma

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Chia Tai Tianqing

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Jiangsu Hengrui Pharmaceuticals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Innovent

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bio-Thera Solutions

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. SinoCellTech

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shanghai Henlius Biotech

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Zhejiang Beta Pharma

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bevacizumab Generics Market

Figure 4: Global Bevacizumab Generics Market: Drivers

Figure 5: Global Bevacizumab Generics Market: Challenges

Figure 6: Global Bevacizumab Generics Market: Trends

Figure 7: Global Bevacizumab Generics Market: Opportunity

Figure 8: Global Bevacizumab Generics Market: Restraint

Figure 9: Global Bevacizumab Generics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Bevacizumab Generics Market Value (USD Million) By Region

Figure 19: Global Bevacizumab Generics Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Bevacizumab Generics Market Value (USD Million) By Region

Figure 27: Global Bevacizumab Generics Market Share (%) By: Regions (2032)

Figure 28: Global Bevacizumab Generics Market Volume (K) By Region

Figure 29: Global Bevacizumab Generics Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Bevacizumab Generics Market Value (USD Million) By Region

Figure 37: Global Bevacizumab Generics Market Share (%) By: Regions (2032)

Figure 38: Global Bevacizumab Generics Market Volume (K) By Region

Figure 39: Global Bevacizumab Generics Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Bevacizumab Generics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Bevacizumab Generics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Bevacizumab Generics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Bevacizumab Generics Market Value (USD Million) By Region

Table 14: Global Bevacizumab Generics Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Bevacizumab Generics Market Volume (K) By Region

Table 31: Global Bevacizumab Generics Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Bevacizumab Generics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Bevacizumab Generics Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Bevacizumab Generics Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Amneal Pharmaceuticals Basic Information And Sales Area

Table 52: Amneal Pharmaceuticals. Products Portfolio

Table 53: Amgen Basic Information And Sales Area

Table 54: Amgen. Products Portfolio

Table 55: Celltrion Healthcare Basic Information And Sales Area

Table 56: Celltrion Healthcare. Products Portfolio

Table 57: Pfizer Basic Information And Sales Area

Table 58: Pfizer. Products Portfolio

Table 59: Qilu Pharma Basic Information And Sales Area

Table 60: Qilu Pharma. Products Portfolio

Table 61: Chia Tai Tianqing Basic Information And Sales Area

Table 62: Chia Tai Tianqing. Products Portfolio

Table 63: Jiangsu Hengrui Pharmaceuticals Basic Information And Sales Area

Table 64: Jiangsu Hengrui Pharmaceuticals. Products Portfolio

Table 65: Innovent Basic Information And Sales Area

Table 66: Innovent. Products Portfolio

Table 67: Bio-Thera Solutions Basic Information And Sales Area

Table 68: Bio-Thera Solutions. Products Portfolio

Table 69: SinoCellTech Basic Information And Sales Area

Table 70: SinoCellTech. Products Portfolio

Table 71: Shanghai Henlius Biotech Basic Information And Sales Area

Table 72: Shanghai Henlius Biotech. Products Portfolio

Table 73: Zhejiang Beta Pharma Basic Information And Sales Area

Table 74: Zhejiang Beta Pharma. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Type

Table 76: Global Market Share (%) By Type (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Type

Table 80: Global Market Share (%) By Type (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Bevacizumab Generics Market Value (USD Million) By Region

Table 84: Global Bevacizumab Generics Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Type

Table 87: North America Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Type

Table 90: Europe Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Type

Table 96: South America Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 100: Global Bevacizumab Generics Market Volume (K) By Region

Table 101: Global Bevacizumab Generics Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Type

Table 104: North America Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Type

Table 107: Europe Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Type

Table 113: South America Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

FAQs

1. What is the current Bevacizumab Generics market size?

The global Bevacizumab Generics market size surpassed USD 1.4 billion in 2023, driven by rising biosimilar adoption and patent expiries across major markets.

2. What is the future outlook and growth forecast for Bevacizumab Generics?

Analysts project a 9–11% CAGR through 2030, lifting the segment to nearly USD 2.7 billion as cost-containment policies favor biosimilars over originator biologics.

3. What are the key drivers propelling the Bevacizumab Generics market?

Key drivers include originator patent cliffs, payer pressure to cut oncology drug spend, expanding indications, and proven pharmacoeconomic benefits of biosimilars.

4. Which challenges currently restrain Bevacizumab Generics uptake?

Interchangeability hurdles, varying regulatory standards, physician skepticism on biosimilar efficacy, and lengthy price erosion cycles constrain faster volume ramp-up.

5. Which regions lead Bevacizumab Generics demand?

North America and Europe together hold over 70% share, while China, India, and LATAM emerge as high-growth hubs due to tender-based procurement and favorable biosimilar policy.

6. Who are the top companies in the Bevacizumab Generics space?

Leading players include Amgen, Samsung Bioepis, Pfizer, Celltrion, Mylan/Viatris, and Reliance Life Sciences, each leveraging regional partnerships to secure formulary placement.

7. What future opportunities can stakeholders exploit?

Opportunities lie in developing high-concentration formulations, pursuing oncology combination trials, and entering emerging markets where originator access remains limited.

8. How is technology reshaping Bevacizumab Generics manufacturing?

Single-use bioreactors, continuous bioprocessing, and AI-driven analytics cut COGS by up to 30%, enabling competitive pricing while maintaining pharmacovigilance standards.

9. What is the current regulatory landscape for Bevacizumab Generics?

Stringent comparability exercises, extrapolation pathways, and real-world evidence mandates define FDA and EMA approvals; China’s NMPA now offers 12-month accelerated review.

10. Will interchangeability designations significantly boost market share?

Yes—interchangeability allows pharmacy-level substitution in the U.S., potentially doubling volume share within two years and anchoring favorable formulary tier placement.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Bevacizumab Generics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	7.13 million
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amneal Pharmaceuticals; Amgen; Celltrion Healthcare; Pfizer; Qilu Pharma; Chia Tai Tianqing; Jiangsu Hengrui Pharmaceuticals; Innovent; Bio-Thera Solutions; SinoCellTech; Shanghai Henlius Biotech; Zhejiang Beta Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options